Michael Cecchini, MD, highlights his latest research evaluating the efficacy of neoadjuvant mFOLFIRINOX in improving survival and controlling micrometastasis in resectable pancreatic ductal adenocarcinoma. Dr. Cecchini also discusses how circulating tumor DNA was used in this study as well as which methods were used for collecting and analyzing ctDNA levels. ...
Advertisement
Kidney care provider Evergreen Nephrology has added David Young to its board of directors.
In March, a patient at the Cleveland Clinic became the first in the US to receive a robot-assisted dual kidney transplant.
MDS experts tell of the clinical factors they consider when selecting from the available agent options.
The trial is the first to evaluate the investigational telomere-targeting agent with a PD-(L)1 inhibitior.
Are kidneys from donors who had dialysis more likely to result in adverse outcomes for transplant recipients?
Grace-Ann Fasaye discusses the elevated lifetime risk of gastric cancer in patients with CDH1 gene variants.
A gift from the Schattner Foundation will support the American Kidney Fund's disaster relief program and other programs.
An MDS expert panel discusses findings from the trial's comparison of luspatercept with ESAs in this setting.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Grace-Ann Fasaye discusses the elevated lifetime risk of gastric cancer in patients with CDH1 gene variants.
The AI model used predictors of recurrence and duration imatinib treatment to determine recurrence risk.
Participants received pemigatinib 13.5 mg once per day for 21-day cycles with 2 weeks on and 1 week off.
Researchers examined TAS102 with regorafenib to determine if the combination is active in CRC and other GI malignancies.
While immunotherapy paired with VEGF inhibitors are considered first-line options, they only provide modest efficacy.
Dr. Timothy Brown speaks about his career and his passion for gastrointestinal oncology research and patient care.
The Latest From Heme Today
MDS experts tell of the clinical factors they consider when selecting from the available agent options.
An MDS expert panel discusses findings from the trial's comparison of luspatercept with ESAs in this setting.
Mairéad Ní Chonghaile, RGN, BNS, MSc, speaks on the need for training and support networks in this area of care.
Phase II study data demonstrate this benefit in patients with low-risk myeloid malignancies or precursor conditions.
Final data from a phase II trial suggest a promising option for elderly patients with this serious disease.
Dr. Chedid brings an update highlighting the most noteworthy recent findings from MDS clinical trials.
